REGENERON AXOKINE AND BDNF THERAPIES ARE FOCUS OF NEW R&D STRATEGY
Executive Summary
REGENERON AXOKINE AND BDNF THERAPIES ARE FOCUS OF NEW R&D STRATEGY in the wake of the company's decision June 23 to discontinue Phase III clinical trials of its ciliary neurotrophic factor for the treatment of amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease). As part of its "revised strategic direction" Regeneron will also concentrate on neurotrophin-3 (NT- 3), combinations of neurotrophic factors and a ligand discovery program.